Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26178100 | 0.98 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL11936429 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL29843924 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL6850969 | 0.78 | SMN1; SMN2 (0.94) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL827936 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMAPTEPHX1 | |
| SCHEMBL12236955 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL23736058 | 0.76 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL3076504 | 0.76 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL2377367 | 0.76 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL8165938 | 0.76 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SMN1; SMN2 1553/4885NPC1 265/4885RAB9A 2563/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | SMN1; SMN2 3613/4885NPC1 481/4885RAB9A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.